{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:58:20Z","timestamp":1753891100811,"version":"3.41.2"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>While most thyroid cancer patients have a favorable prognosis, anaplastic thyroid carcinoma (ATC) remains a particularly aggressive form with a median survival time of just five months. Conventional therapies offer limited benefits for this type of thyroid cancer. Our study aims to identify ATC patients who might bene t from immunotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Our study uses multiple algorithms by R4.2.0, and gene expression and clinical data are collected from TCGA, GEO and local cohort. In vitro experiments, such as western blot and immunofluorescence staining, are performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Using a set of five genes uniquely expressed across various types of thyroid cancer, we developed a machine-learning model to distinguish each type within the GEO dataset of thyroid cancer patients (GSE60542, GSE76039, GSE33630, GSE53157, GSE65144, GSE29265, GSE82208, GSE27155, GSE58545, GSE54958, and GSE32662). These genes allowed us to stratify ATC into three distinct groups, each exhibiting significantly different responses to anti-PD1 therapy as determined by consensus clustering. Through weighted gene co-expression network analysis (WGCNA), we identified 12 differentially expressed genes closely associated with immunotherapy outcomes. This led to the creation of a refined signature for predicting ATC\u2019s immune responsiveness to anti-PD1 therapy, which was further validated using thyroid cancer cohorts from TCGA and nine melanoma cohorts from clinical trials. Among the 12 genes, HLF stood out due to its strong association with various cancer hallmarks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Our study revealed that HLF impedes ATC progression by down-regulating the epithelial-to-mesenchymal transition (EMT) pathway, reducing T cell exhaustion, and increasing sensitivity to sorafenib, as demonstrated through our <jats:italic>in-vitro<\/jats:italic> experiments.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1478904","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T06:13:27Z","timestamp":1736748807000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Construction of an anaplastic thyroid cancer stratification signature to guide immune therapy selection and validation of the pivotal gene HLF through in vitro experiments"],"prefix":"10.3389","volume":"15","author":[{"given":"Li","family":"Pengping","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin","family":"Kexin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xie","family":"Yuwei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Rongguo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Zhenyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Haigang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Shaowen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huang","family":"Yuqing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14041061","article-title":"Anaplastic\u00a0thyroid carcinoma: an update","volume":"14","author":"Jannin","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-20-0080","article-title":"Anaplastic thyroid carcinoma: a nationwide cohort study on incidence, treatment and survival in the Netherlands over 3 decades","volume":"183","author":"de Ridder","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae443","article-title":"A phase I\/II trial\u00a0of\u00a0sapanisertib in advanced anaplastic and radioiodine refractory differentiated thyroid carcinoma","author":"Sehgal","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1055\/a-1089-7870","article-title":"Updates on the management of thyroid cancer","volume":"52","author":"Araque","year":"2020","journal-title":"Horm Metab Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0435","article-title":"Anaplastic thyroid carcinoma: review of treatment protocols","volume":"25","author":"Tiedje","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v15.i6.684","article-title":"Current status of anaplastic thyroid carcinoma","volume":"15","author":"Ocanto","year":"2024","journal-title":"World J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v14.i12.570","article-title":"Update on current diagnosis and management of anaplastic thyroid carcinoma","volume":"14","author":"Pavlidis","year":"2023","journal-title":"World J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91095","article-title":"DNA methylation-based immune response signature improves patient diagnosis in multiple cancers","volume":"127","author":"Jeschke","year":"2017","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","first-page":"100293","DOI":"10.1016\/j.patter.2021.100293","article-title":"Interpretable systems biomarkers predict response to immune-checkpoint inhibitors","volume":"2","author":"Lapuente-Santana","year":"2021","journal-title":"Patterns (N Y)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky939","article-title":"CancerSEA: a cancer\u00a0single-cell state atlas","volume":"47","author":"Yuan","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1000217","article-title":"Inferring pathway activity toward precise disease classification","volume":"4","author":"Lee","year":"2008","journal-title":"PloS Comput Biol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.649029","article-title":"FHL3 contributes to EMT and chemotherapy resistance through up-regulation of slug and activation of TGF\u03b2\/smad-independent pathways in gastric cancer","volume":"11","author":"Cao","year":"2021","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.18632\/aging.102564","article-title":"FHL3 promotes pancreatic cancer invasion and metastasis through preventing the ubiquitination degradation of EMT associated transcription factors","volume":"12","author":"Li","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12957-019-1755-9","article-title":"BCL2 and hsa-miR-181a-5p are potential biomarkers associated with papillary thyroid cancer based on bioinformatics analysis","volume":"17","author":"Zhang","year":"2019","journal-title":"World J Surg Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2017.02.028","article-title":"Inhibition of MAPKinase pathway sensitizes thyroid cancer cells to ABT-737 induced apoptosis","volume":"395","author":"Gunda","year":"2017","journal-title":"Cancer Lett"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-14-0268","article-title":"Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression","volume":"21","author":"Champa","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s10495-022-01780-7","article-title":"BCL-2 protein family: attractive targets for cancer therapy","volume":"28","author":"Kaloni","year":"2023","journal-title":"Apoptosis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-0942","article-title":"Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition","volume":"92","author":"Mitsiades","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","first-page":"105695","DOI":"10.1016\/j.jbc.2024.105695","article-title":"The BHLHE40\u2212PPM1F\u2212AMPK pathway regulates energy metabolism and is associated with the aggressiveness of endometrial cancer","volume":"300","author":"Asanoma","year":"2024","journal-title":"J Biol Chem"},{"key":"B20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13008-024-00129-7","article-title":"Long non-coding RNA NEAT1 induced by BHLHE40 activates Wnt\/\u03b2-catenin signaling and potentiates colorectal cancer progression","volume":"19","author":"Ji","year":"2024","journal-title":"Cell Div"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-3264","article-title":"Single-cell and spatial transcriptome profiling identifies the transcription factor BHLHE40 as a driver of EMT in metastatic colorectal cancer","volume":"84","author":"Yang","year":"2024","journal-title":"Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202306298","article-title":"BHLHE40 inhibits ferroptosis in pancreatic cancer cells via upregulating SREBF1","volume":"11","author":"Cao","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1055\/a-2196-3511","article-title":"LncRNA H19 Influences Cellular Activities via the miR-454-3p\/BHLHE40 Axis in Anaplastic Thyroid Carcinoma","volume":"56","author":"Wu","year":"2024","journal-title":"Horm Metab Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1101\/2024.06.26.600548","article-title":"MICAL2 is a super enhancer associated gene that promotes pancreatic cancer growth and metastasis","author":"Garg","year":"2024","journal-title":"bioRxiv"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1038\/s41598-024-52729-6","article-title":"MICAL2 implies immunosuppressive features and acts as an independent and adverse prognostic biomarker in pancreatic cancer","volume":"14","author":"Liu","year":"2024","journal-title":"Sci Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010518","article-title":"Comprehensive analysis of MICALL2 reveals its potential roles in EGFR stabilization and ovarian cancer cell invasion","volume":"25","author":"Xia","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.62347\/OBES4130","article-title":"The upregulation of TGM2 is associated with poor prognosis and the shaping of the inflammatory tumor microenvironment in lung squamous cell carcinoma","volume":"14","author":"Chang","year":"2024","journal-title":"Am J Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jproteome.4c00379","article-title":"Chemical proteomic profiling of protein dopaminylation in colorectal cancer cells","volume":"23","author":"Zhang","year":"2024","journal-title":"J Proteome Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"10848","DOI":"10.1038\/s41598-023-37932-1","article-title":"TPO as an indicator of lymph node metastasis and recurrence in papillary thyroid carcinoma","volume":"13","author":"Li","year":"2023","journal-title":"Sci Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41419-023-06076-5","article-title":"HLF promotes ovarian cancer progression and chemoresistance via regulating Hippo signaling pathway","volume":"14","author":"Han","year":"2023","journal-title":"Cell Death Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13045-021-01223-x","article-title":"HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk","volume":"15","author":"Li","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-317440","article-title":"Oncofetal HLF transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance","volume":"68","author":"Xiang","year":"2019","journal-title":"Gut"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1478904\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T06:13:30Z","timestamp":1736748810000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1478904\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2024.1478904"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1478904","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"article-number":"1478904"}}